Other authors have found a higher risk of depressive disorders in patients with BC at the age of 40–59, this risk increasing for those patients who had undergone adjuvant therapies including CT, radiotherapy, tamoxifen, third-generation aromatase inhibitors, or trastuzumab [56]. Here, CYP19A1 is linked to depressive disorder.